Evotec unveiled a major restructuring that will eliminate up to 800 positions—about one‑sixth of its global workforce—and close four facilities as part of a cost‑cutting and refocusing program dubbed “Horizons.” The company said the moves concentrate scientific resources into Centers of Excellence and prioritize higher‑value discovery and preclinical services. Management framed the downsizing as necessary to accelerate execution, improve responsiveness to pharma clients, and align capabilities with market demand. The plan preserves key hubs for biologics and process engineering but shutters several discovery and omics sites, including locations in Framingham and Munich. Customers and CRO partners will be watching site closures and capacity shifts closely, since Evotec serves major pharma and hundreds of biotechs. The restructuring could reconfigure outsourcing capacity in Europe and the U.S. as Evotec narrows its service footprint and evolves its commercial model.